Your browser doesn't support javascript.
loading
Primary hyperparathyroidism as first manifestation in multiple endocrine neoplasia type 2A: an international multicenter study.
Larsen, Louise Vølund; Mirebeau-Prunier, Delphine; Imai, Tsuneo; Alvarez-Escola, Cristina; Hasse-Lazar, Kornelia; Censi, Simona; Castroneves, Luciana A; Sakurai, Akihiro; Kihara, Minoru; Horiuchi, Kiyomi; Barbu, Véronique Dorine; Borson-Chazot, Francoise; Gimenez-Roqueplo, Anne-Paule; Pigny, Pascal; Pinson, Stephane; Wohllk, Nelson; Eng, Charis; Aydogan, Berna Imge; Saranath, Dhananjaya; Dvorakova, Sarka; Castinetti, Frederic; Patocs, Attila; Bergant, Damijan; Links, Thera P; Peczkowska, Mariola; Hoff, Ana O; Mian, Caterina; Dwight, Trisha; Jarzab, Barbara; Neumann, Hartmut P H; Robledo, Mercedes; Uchino, Shinya; Barlier, Anne; Godballe, Christian; Mathiesen, Jes Sloth.
Afiliação
  • Larsen LV; Department of ORL Head & Neck Surgery and Audiology, Odense University Hospital, Odense, Denmark.
  • Mirebeau-Prunier D; Laboratoire de Biochimie et Biologie Moléculaire, CHU Angers, Université d'Angers, UMR CNRS 6015, INSERM U1083, MITOVASC, Angers, France.
  • Imai T; Department of Breast & Endocrine Surgery, National Hospital Organization, Higashinagoya National Hospital, Nagoya, Japan.
  • Alvarez-Escola C; Endocrinology and Nutrition Department, University Hospital 'La Paz', Madrid, Spain.
  • Hasse-Lazar K; Department of Nuclear Medicine and Endocrine Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice Branch, Gliwice, Poland.
  • Censi S; Endocrinology Unit, Department of Medicine (DIMED), University of Padua, Padua, Italy.
  • Castroneves LA; Department of Endocrinology, Endocrine Oncology Unit, Instituto do Cancer do Estado de São Paulo, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil.
  • Sakurai A; Department of Medical Genetics and Genomics, Sapporo Medical University School of Medicine, Sapporo, Japan.
  • Kihara M; Department of Surgery, Kuma Hospital, Kobe, Hyogo, Japan.
  • Horiuchi K; Department of Breast and Endocrine Surgery, Tokyo Women's Medical University, Tokyo, Japan.
  • Barbu VD; AP-HP, Sorbonne Université, Laboratoire Commun de Biologie et Génétique Moléculaires, Hôpital St Antoine & INSERM CRSA, Paris, France.
  • Borson-Chazot F; Réseau TenGen, Marseille, France.
  • Gimenez-Roqueplo AP; Réseau TenGen, Marseille, France.
  • Pigny P; Fédération d'Endocrinologie, Hospices Civils de Lyon, Université Lyon 1, France.
  • Pinson S; Réseau TenGen, Marseille, France.
  • Wohllk N; Service de Génétique, AP-HP, Hôpital européen Georges Pompidou, Paris, France.
  • Eng C; Université de Paris, PARCC, INSERM, Paris, France.
  • Aydogan BI; Réseau TenGen, Marseille, France.
  • Saranath D; Laboratoire de Biochimie et Oncologie Moléculaire, CHU Lille, Lille, France.
  • Dvorakova S; Réseau TenGen, Marseille, France.
  • Castinetti F; Laboratoire de Génétique Moléculaire, CHU Lyon, Lyon, France.
  • Patocs A; Endocrine Section, Hospital del Salvador, Santiago de Chile, Department of Medicine, University of Chile, Santiago, Chile.
  • Bergant D; Genomic Medicine Institute, Lerner Research Institute and Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, USA.
  • Links TP; Department of Endocrinology And Metabolic Diseases, Ankara University School of Medicine, Ankara, Turkey.
  • Peczkowska M; Department of Research Studies & Additional Projects, Cancer Patients Aid Association, Dr. Vithaldas Parmar Research & Medical Centre, Worli, Mumbai, India.
  • Hoff AO; Department of Molecular Endocrinology, Institute of Endocrinology, Prague, Czech Republic.
  • Mian C; Aix-Marseille Université, Institut National de la Santé et de la Recherche Médicale (INSERM), U1251, Marseille Medical Genetics (MMG), Marseille, France.
  • Dwight T; Department of Endocrinology, Assistance Publique-Hôpitaux de Marseille (AP-HM), Hôpital de la Conception, Centre de Référence des Maladies Rares de l'hypophyse HYPO, Marseille, France.
  • Jarzab B; HAS-SE Momentum Hereditary Endocrine Tumors Research Group, Semmelweis University, Budapest, Hungary.
  • Neumann HPH; Department of Surgical Oncology, Institute of Oncology, Ljubljana, Slovenia.
  • Robledo M; Department of Endocrinology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands.
  • Uchino S; Department of Hypertension, Institute of Cardiology, Warsaw, Poland.
  • Barlier A; Department of Endocrinology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands.
  • Godballe C; Endocrinology Unit, Department of Medicine (DIMED), University of Padua, Padua, Italy.
  • Mathiesen JS; Cancer Genetics, Kolling Institute, Royal North Shore Hospital and University of Sydney, Sydney, New South Wales, Australia.
Endocr Connect ; 9(6): 489-497, 2020 Jun.
Article em En | MEDLINE | ID: mdl-32375120
OBJECTIVE: Multiple endocrine neoplasia type 2A (MEN 2A) is a rare syndrome caused by RET germline mutations and has been associated with primary hyperparathyroidism (PHPT) in up to 30% of cases. Recommendations on RET screening in patients with apparently sporadic PHPT are unclear. We aimed to estimate the prevalence of cases presenting with PHPT as first manifestation among MEN 2A index cases and to characterize the former cases. DESIGN AND METHODS: An international retrospective multicenter study of 1085 MEN 2A index cases. Experts from MEN 2 centers all over the world were invited to participate. A total of 19 centers in 17 different countries provided registry data of index cases followed from 1974 to 2017. RESULTS: Ten cases presented with PHPT as their first manifestation of MEN 2A, yielding a prevalence of 0.9% (95% CI: 0.4-1.6). 9/10 cases were diagnosed with medullary thyroid carcinoma (MTC) in relation to parathyroid surgery and 1/10 was diagnosed 15 years after parathyroid surgery. 7/9 cases with full TNM data were node-positive at MTC diagnosis. CONCLUSIONS: Our data suggest that the prevalence of MEN 2A index cases that present with PHPT as their first manifestation is very low. The majority of index cases presenting with PHPT as first manifestation have synchronous MTC and are often node-positive. Thus, our observations suggest that not performing RET mutation analysis in patients with apparently sporadic PHPT would result in an extremely low false-negative rate, if no other MEN 2A component, specifically MTC, are found during work-up or resection of PHPT.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Guideline / Risk_factors_studies Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Guideline / Risk_factors_studies Idioma: En Ano de publicação: 2020 Tipo de documento: Article